Bosutinib - related pleural effusion in patients with chronic myeloid leukemia

被引：5

作者：

Yuzbasioglu, Mebrure Burcak ^{[1
]}

Eskazan, Ahmet Emre ^{[2
]}

机构：

[1] Istanbul Univ Cerrahpasa, Dept Internal Med, Cerrahpasa Fac Med, Istanbul, Turkey

[2] Istanbul Univ Cerrahpasa, Dept Internal Med, Cerrahpasa Fac Med, Div Hematol, Istanbul, Turkey

来源：

EXPERT OPINION ON DRUG SAFETY | 2021年 / 20卷 / 04期

关键词：

Adverse event; bosutinib; chronic myeloid leukemia; pleural effusion; tyrosine kinase inhibitor; KINASE INHIBITOR; DASATINIB; IMATINIB; LYMPHOCYTOSIS;

D O I：

10.1080/14740338.2021.1867103

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：379 / 381

页数：3

共 27 条

[1]

[Anonymous], 2016, Expert Rev Qual Life Cancer Care

[2]

Cortes JE, 2017, J CLIN ONCOL, V17, pS316

[3] Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial [J].

Cortes, Jorge E. ;

Gambacorti-Passerini, Carlo ;

Deininger, Michael W. ;

Mauro, Michael J. ;

Chuah, Charles ;

Kim, Dong-Wook ;

Dyagil, Irina ;

Glushko, Nataliia ;

Milojkovic, Dragana ;

le Coutre, Philipp ;

Garcia-Gutierrez, Valentin ;

Reilly, Laurence ;

Jeynes-Ellis, Allison ;

Leip, Eric ;

Bardy-Bouxin, Nathalie ;

Hochhaus, Andreas ;

Brummendorf, Tim H. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :231-+

[4] Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib [J].

Cortes, Jorge E. ;

Khoury, Hanna J. ;

Kantarjian, Hagop M. ;

Lipton, Jeff H. ;

Kim, Dong-Wook ;

Schafhausen, Philippe ;

Matczak, Ewa ;

Leip, Eric ;

Noonan, Kay ;

Bruemmendorf, Tim H. ;

Gambacorti-Passerini, Carlo .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (12) :1206-1214

[5] Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial [J].

Cortes, Jorge E. ;

Kim, Dong-Wook ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Dyagil, Irina ;

Griskevicius, Laimonas ;

Malhotra, Hemant ;

Powell, Christine ;

Gogat, Karin ;

Countouriotis, Athena M. ;

Gambacorti-Passerini, Carlo .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (28) :3486-3492

[6] Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib [J].

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Bruemmendorf, Tim H. ;

Kim, Dong-Wook ;

Turkina, Anna G. ;

Shen, Zhi-Xiang ;

Pasquini, Ricardo ;

Khoury, H. Jean ;

Arkin, Steven ;

Volkert, Angela ;

Besson, Nadine ;

Abbas, Richat ;

Wang, Junyuan ;

Leip, Eric ;

Gambacorti-Passerini, Carlo .

BLOOD, 2011, 118 (17) :4567-4576

[7] Bosutinib - an effective and safe treatment option in the management of chronic myeloid leukemia [J].

Ercaliskan, Abdulkadir ;

Eskazan, Ahmet Emre .

FUTURE ONCOLOGY, 2020, 16 (03) :4425-4428

[8]

Eskazan AE, 2011, HAEMATOLOGICA, V96, pe15

[9] Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest? [J].

Eskazan, Ahmet Emre .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (10) :2241-2243

[10] Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good? [J].

Eskazan, Ahmet Emre ;

Ozmen, Deniz .

EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (07) :583-586

← 1 2 3 →